ASC40 meaningfully reduces liver fat in Phase II NASH trial
ASC40 reduced liver fat and significantly lowered an enzyme associated…
ASC40 reduced liver fat and significantly lowered an enzyme associated with liver inflammation in nonalcoholic steatohepatitis (NASH) patients.